Publications associées à Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Peptide-based virucidal drugs

Before the COVID-19 pandemic, viruses were not a major priority for the scientific community. Today, many events have changed the world and the importance of studying viruses, vaccines, and antiviral drugs is fully appreciated. The development of effective ...

EPFL2024

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Philippe Colin, Aleksandar Antanasijevic

Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the persistent fraction of infectivity at maximum neutralizat ...

Public Library Science2023

Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph Nodes

Myriam Isabelle Lamrayah

Vaccine technology is still facing challenges regarding some infectious diseases, which can be addressed by innovative drug delivery systems. In particular, nanoparticle-based vaccines combined with new types of adjuvants are actively explored as a platfor ...

MDPI2023

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma

Didier Trono, Priscilla Turelli, Marc Emmenegger

The clinical outcome of SARS-CoV-2 infections, which can range from asymptomatic to lethal, is crucially shaped by the concentration of antiviral antibodies and by their affinity to their targets. However, the affinity of polyclonal antibody responses in p ...

LIFE SCIENCE ALLIANCE LLC2022

Emerging dimensions of cellular cGAS-STING signaling

Andrea Ablasser, Baptiste Claude André Guey

The recognition of DNA through the cGAS-STING pathway plays a critical role in antiviral immunity, but can also drive maladaptive immune responses underlying several pathological conditions. Despite its importance, understanding the organization of cGAS-ST ...

2022

Identification of Vaccine Effects When Exposure Status Is Unknown

Mats Julius Stensrud

Results from randomized controlled trials (RCTs) help determine vaccination strategies and related public health policies. However, defining and identifying estimands that can guide policies in infectious disease settings is difficult, even in an RCT. The ...

2023

A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma

Didier Trono, Priscilla Turelli, Florence Pojer, Charlène Mireille Raymonde Raclot, Valeria Cagno, Jérémy Campos, Céline Pellaton

The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the serum of an individual indicates previous infection or vaccination. However, it provides limited insight into the protective nature of this immune resp ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic

Francesco Stellacci

The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. ...

AMER CHEMICAL SOC2020

Adjuvant-free immunization with infective filarial larvae as lymphatic homing antigen carriers

Melody Swartz, Marcela Rincón-Restrepo, Sachiko Hirosue, Witold Waldemar Kilarski, Alexandre de Titta, Esra Güç, David Scott Wilson

Controlled infection with intestinal nematodes has therapeutic potential for preventing the symptoms of allergic and autoimmune diseases. Here, we engineered larvae of the filarial nematode Litomosoides sigmodontis as a vaccine strategy to induce adaptive ...

Nature Research2020

Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity

Davide Demurtas

Author summary Human cytomegalovirus (HCMV) infection is the foremost viral cause of congenital birth defects. Attempts to vaccinate against HCMV brought moderate, though not sufficient, reduction in infection. Moreover, phase II clinical trial with gB for ...

2020